
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is well positioned within the evolving field of Wnt therapeutics, with its dual Wnt/ anti-VEGF antibody SZN-8141 entering the clinic in DME patients by the end of 3Q26 for the treatment of retinal vascular diseases. With a successful trial outcome, the company could potentially see an initial data catalyst in 2H27. Additionally, Surrozen's recent update from the US Patent Trial and Appeal Board (PTAB) denying the institution of a post-grant review petition reinforces the company's intellectual property position. The company reported strong Q2 2026 financials, with a net gain of $50.2M and $102.0M in cash and equivalents. With a diverse pipeline and promising preclinical data, Surrozen is poised for success in the treatment of retinal diseases.
Bears say
Surrozen is currently in the clinical-stage of development of its Wnt pathway modulating drugs, and while they have upcoming milestones such as IND submission and initiation of a Phase 1b/2a trial, the market will be looking for initial evidence of safety, tolerability, and clinical activity. With traditional anti-VEGF wet AMD treatments having shown improvements in durability, Surrozen's potential for improved efficacy, longer-lasting results, and reduced injection frequency is promising. However, there are significant risks involved in the success of their developmental candidates and their ability to secure funding for operations.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares